Status:
RECRUITING
The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy
Lead Sponsor:
Anna Stanhewicz, PhD
Conditions:
Gestational Diabetes Mellitus (GDM)
Postpartum Women
Eligibility:
FEMALE
18-50 years
Phase:
PHASE1
Brief Summary
Gestational Diabetes Mellitus (GDM) currently affects approximately 14% of all pregnancies worldwide. Importantly, the health-related consequences of GDM extend well beyond pregnancy, such that women ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Post-partum women
- 18 years or older
- Delivered within 5 years from the study visit
- History of gestational diabetes diagnosed by an obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes OR history of uncomplicated pregnancy (defined as no history of gestational diabetes, hypertensive pregnancy, or other gestational disorder).
- EXCLUSION CRITERIA: We exclude participants from both groups for:
- Skin diseases
- Current tobacco use
- Diagnosed or suspected hepatic or metabolic disease including diabetes
- Diagnosed with depression or other mood-related disorders, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or pulmonary fibrosis
- Use of prescribed NSAIDs, statins or other cholesterol-lowering medication, antihypertensive medication, carbonic anhydrase inhibitors, corticosteroids, thyroid medications, antidepressants or mood stabilizers, diuretics, phenothiazines, or benzodiazepines
- History of preeclampsia or gestational hypertension,
- History or family history of panic disorder,
- Currently pregnant
- Body mass index \<18.5 kg/m2,
- Allergy to materials used during the experiment (e.g. latex), known allergies to study drugs.
- History of heavy alcohol use/binge drinking,
- Have planned procedures with radiological contrast,
- Have a major dental procedure/surgery coming up, such as a dental extraction
- Anatomy of the middle cerebral artery or internal carotid artery that prevents adequate ultrasonography and/or and data collection
Exclusion
Key Trial Info
Start Date :
August 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2028
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06911372
Start Date
August 22 2025
End Date
April 15 2028
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Iowa Bioscience Innovation Facility
Iowa City, Iowa, United States, 52242